Harvard Study: Half of Adult Americans Eligible for Ozempic-Like Drugs
By Peter A. McCullough, MD, MPH Glucagon-like peptide receptor agonists (GLP-1 RA) are the current financial rainmakers for BIG PHARMA. Shi et al from Harvard reported recently in JAMA Cardiology. Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion. Quantifying the number of […]
Discuss on Nostr!
Nostr Note ID note1hpxtccz2q2a43p0k9l07mfv9xt74y45gvg5zwtwgc257gehl39uqdvf9fn Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.